Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other financing activities: 2014-2024

Historic Other financing activities for Theravance Biopharma (TBPH) over the last 11 years, with Dec 2024 value amounting to $2.7 million.

  • Theravance Biopharma's Other financing activities rose 70.78% to $678,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2.53%. This contributed to the annual value of $2.7 million for FY2024, which is 6.36% up from last year.
  • According to the latest figures from FY2024, Theravance Biopharma's Other financing activities is $2.7 million, which was up 6.36% from $2.5 million recorded in FY2023.
  • Theravance Biopharma's 5-year Other financing activities high stood at $9.1 million for FY2021, and its period low was -$20.2 million during FY2022.
  • Moreover, its 3-year median value for Other financing activities was $2.5 million (2023), whereas its average is -$5.0 million.
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 629.34% in 2020, then soared by 153.95% in 2021.
  • Yearly analysis of 5 years shows Theravance Biopharma's Other financing activities stood at -$16.8 million in 2020, then spiked by 153.95% to $9.1 million in 2021, then tumbled by 322.81% to -$20.2 million in 2022, then spiked by 112.38% to $2.5 million in 2023, then grew by 6.36% to $2.7 million in 2024.